SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/331171"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/331171" > Methotrexate safety...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004097naa a2200505 4500
001oai:gup.ub.gu.se/331171
003SwePub
008240528s2024 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:154689976
0247 a https://gup.ub.gu.se/publication/3311712 URI
0247 a https://doi.org/10.1002/art.427302 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1546899762 URI
040 a (SwePub)gud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Lend, Kristinau Karolinska Institutet4 aut
2451 0a Methotrexate safety and efficacy in combination therapies in patients with early rheumatoid arthritis: a post-hoc analysis of a randomized controlled trial (NORD-STAR).
264 1c 2024
520 a To investigate methotrexate safety and influence of dose on efficacy outcomes in combination with three different biological treatments and with active conventional treatment (ACT) in early rheumatoid arthritis (RA).This post-hoc analysis included 812 treatment-naïve early RA patients who were randomized (1:1:1:1) in the NORD-STAR trial (NCT01491815) to receive methotrexate in combination with ACT, certolizumab-pegol, abatacept, or tocilizumab. Methotrexate safety, doses, and dose effects on Clinical Disease Activity Index (CDAI) remission were assessed after 24weeks of treatment.Compared with ACT, the prevalence of methotrexate-associated side effects was higher when methotrexate was combined with tocilizumab (HR 1.48 [95% CI 1.20 to 1.84]), but not with certolizumab-pegol (HR 0.99 [0.79 to 1.23]) or with abatacept (HR 0.93 [0.75 to 1.16]). With ACT as the reference, methotrexate dose was significantly lower when used in combination with tocilizumab (β -4.65 [95% CI -5.83 to -3.46], p<0.001), with abatacept (β -1.15 [-2.27 to -0.03], p=0.04), and numerically lower in combination with certolizumab-pegol (β -1.07 [-2.21 to 0.07], p=0.07). Methotrexate dose reductions were not associated with decreased CDAI remission rates within any of the treatment combinations.Methotrexate was generally well tolerated in combination therapies, but adverse events were a limiting factor in receiving the target dose of 25 mg/week, and these were more frequent in combination with tocilizumab versus active conventional treatment. On the other hand, methotrexate dose reductions were not associated with decreased CDAI remission rates within any of the four treatment combinations at 24weeks.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
7001 a Koopman, Frieda A4 aut
7001 a Lampa, Jonu Karolinska Institutet4 aut
7001 a Jansen, Gerrit4 aut
7001 a Hetland, Merete L4 aut
7001 a Uhlig, Till4 aut
7001 a Nordström, Dan4 aut
7001 a Nurmohamed, Michael4 aut
7001 a Gudbjornsson, Bjorn4 aut
7001 a Rudin, Anna,d 1961u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research4 aut0 (Swepub:gu)xrudan
7001 a Østergaard, Mikkel4 aut
7001 a Heiberg, Marte S4 aut
7001 a Sokka-Isler, Tuulikki4 aut
7001 a Hørslev-Petersen, Kim4 aut
7001 a Haavardsholm, Espen A4 aut
7001 a Grondal, Gerdur4 aut
7001 a Twisk, Jos W R4 aut
7001 a van Vollenhoven, Ronald4 aut
7102 a Karolinska Institutetb Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning4 org
7730 t Arthritis & rheumatology (Hoboken, N.J.)g 76:3, s. 363-376q 76:3<363-376x 2326-5205
8564 8u https://gup.ub.gu.se/publication/331171
8564 8u https://doi.org/10.1002/art.42730
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:154689976

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy